公开(公告)号：BRPI1011993A2

公开(公告)日：2021-07-06

申请号：BRPI1011993

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： BRIAN LEDFORD ,  CHAO LIN ,  DYLAN H JACOBS ,  EMANUELE PEROLA ,  FRANÇOIS MALTAIS ,  HONGBO DENG ,  HUAI GAO ,  IOANA DRUTU ,  JOHN J COURT ,  JOHN P DUFFY ,  JOSEPH M KENNEDY ,  LUC FARMER ,  M WOODS WANNAMAKER ,  MARK W LEDEBOER ,  MICHAEL P CLARK ,  MIN JIANG ,  PAUL CHARIFSON ,  RANDAL BYRN ,  RANDY S BETHIEL ,  STEVEN JONES ,  TIANSHENG WANG ,  UPUL K BANDARAGE ,  URSULA A GERMANN ,  WENXIN GU ,  YI ZHOU

IPC: A61K31/506 ,  A61P31/16

Abstract: inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e composição farmacêutica que os compreende. a invenção refere-se a métodos de inibição da replicação de vírus influenza em uma amostra biológica ou paciente, de redução da quantidade de vírus influenza em uma amostra biológica ou paciente e de trata-mento de influenza em um paciente compreendendo administrar à dita a-mostra biológica ou paciente uma quantidade eficaz de um composto representado pela fórmula estrutural (i): ou um sal farmaceuticamente aceitável do mesmo, onde os valores da fórmula estrutura (ia) são conforme aqui descrito. um composto é representado pela fórmula estrutural (ia) ou um sal farmaceuticamente aceitável do mesmo, onde os valores de fórmula es-trutural (ia) são conforme aqui descrito. uma composição farmacêutica compreendendo uma quantidade eficaz de tal composto ou sal farmaceuti-camente aceitável do mesmo e um carreador, adjuvante ou veículo farma-ceuticamente aceitável.

公开(公告)号：AU2004285019B9

公开(公告)日：2011-11-24

申请号：AU2004285019

申请日：2004-10-27

Applicant: VERTEX PHARMA

Inventor： KAI LIN ,  CHAO LIN

IPC: C12N9/50 ,  A61K31/4709 ,  A61K38/05 ,  A61K38/16 ,  C07H21/04 ,  C07K14/18 ,  C12N9/48 ,  C12N15/51 ,  C12N15/86 ,  C12Q1/37 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/50 ,  G01N33/68 ,  G06F17/50

Abstract: The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

公开(公告)号：SG155967A1

公开(公告)日：2009-10-29

申请号：SG2009063751

申请日：2005-09-30

Applicant: VERTEX PHARMA

Inventor： CHAO LIN ,  TAYLOR WILLIAM P

Abstract: The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3- NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

公开(公告)号：ZA200703484B

公开(公告)日：2008-09-25

申请号：ZA200703484

申请日：2007-04-30

Applicant: VERTEX PHARMA

Inventor： CHAO LIN ,  TAYLOR WILLIAM P

IPC: A61K20090101

Abstract: The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype 3. The methods of the invention imply inhibitors such as VX-950 that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

公开(公告)号：PT3141252T

公开(公告)日：2018-11-14

申请号：PT16181549

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： FRANCESCO G SALITURO ,  PAUL CHARIFSON ,  MARK W LEDEBOER ,  TIANSHENG WANG ,  LUC FARMER ,  ANN D KWONG ,  CHAO LIN ,  YI ZHOU ,  MARION W WANNAMAKER ,  BRIAN LEDFORD ,  FRANCOIS MALTAIS ,  HUAI GAO ,  MICHAEL P CLARK ,  UPUL K BANDARAGE ,  RANDY S BETHIEL ,  JOHN J COURT ,  HONGBO DENG ,  IOANA DRUTU ,  JOHN P DUFFY ,  WENXIN GU ,  DYLAN H JACOBS ,  JOSEPH M KENNEDY ,  EMANUELE PEROLA ,  RANDAL BYRN ,  MIN JIANG ,  URSULA A GERMANN ,  STEVEN JONES

IPC: A61K31/506 ,  A61P31/16

公开(公告)号：PT2442809T

公开(公告)日：2016-12-06

申请号：PT10726760

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： MARK W LEDEBOER ,  PAUL CHARIFSON ,  MICHAEL P CLARK ,  UPUL K BANDARAGE ,  RANDY S BETHIEL ,  HONGBO DENG ,  JOHN J COURT ,  IOANA DRUTU ,  JOHN P DUFFY ,  LUC FARMER ,  HUAI GAO ,  WENXIN GU ,  DYLAN H JACOBS ,  JOSEPH M KENNEDY ,  BRIAN LEDFORD ,  FRANCOIS MALTAIS ,  EMANUELE PEROLA ,  TIANSHENG WANG ,  M WOODS WANNAMAKER ,  RANDAL BYRN ,  YI ZHOU ,  CHAO LIN ,  MIN JIANG ,  URSULA A GERMANN ,  STEVEN JONES ,  FRANCESCO G SALITURO ,  ANN DAK-YEE KWONG

IPC: A61K31/506 ,  A61P31/16

公开(公告)号：AU2010210892A1

公开(公告)日：2011-08-11

申请号：AU2010210892

申请日：2010-01-21

Applicant: VERTEX PHARMA

Inventor： KWONG ANN D ,  DANIEL FRANTZ JAMES ,  BARTELS DOUGLAS J ,  CHAO LIN ,  BENJAMIN SHAMES ,  SHEILA SEEPERSAUD ,  LIPPKE JUDITH A ,  KIEFFER TARA L ,  YI ZHOU ,  ZHANG EILEEN Z ,  SULLIVAN JAMES C

IPC: C12Q1/68

Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

公开(公告)号：TR201815272T4

公开(公告)日：2018-11-21

申请号：TR201815272

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： PAUL CHARIFSON ,  P MICHAEL CLARK ,  K UPUL BANDARAGE ,  S RANDY BETHIEL ,  J JOHN COURT ,  HONGBO DENG ,  IOANA DRUTU ,  P JOHN DUFFY ,  LUC FARMER ,  HUAI GAO ,  WENXIN GU ,  H DYLAN JACOBS ,  M JOSEPH KENNEDY ,  W MARK LEDEBOER ,  BRIAN LEDFORD ,  FRANCOIS MALTAIS ,  EMANUELE PEROLA ,  TIANSHENG WANG ,  WOODS M WANNAMAKER ,  RANDAL BYRN ,  YI ZHOU ,  CHAO LIN ,  MIN JIANG ,  A URSULA GERMANN ,  STEVEN JONES ,  FRANCESCO G SALITURO ,  ANN DAK-YEE KWONG

IPC: A61K31/506 ,  A61P31/16

Abstract: Biyolojik bir numunede veya hastada influenza virüslerinin replikasyonunun inhibe edilmesi, biyolojik bir numunede veya hastada influenza virüslerinin miktarının düşürülmesi ve bir hastada influenzanın tedavi edilmesine yönelik yöntemler, söz konusu biyolojik numune veya hastaya, Yapısal Formül (I) ile gösterilen bir bileşiğin etkili bir miktarının: veya bunun farmasötik olarak kabul edilebilir bir tuzunun uygulanmasını içerir, burada Yapısal Formülün (IA) değerleri, burada açıklandığı gibidir. Bir bileşik, Yapısal Formül (IA) veya farmasötik olarak kabul edilebilir bir tuzu ile gösterilir, burada Yapısal Formülün (IA) değerleri, burada açıklandığı gibidir. Farmasötik bir bileşim, bu tür bir bileşiğin veya farmasötik olarak kabul edilebilir bir tuzunun etkili miktarını ve farmasötik olarak kabul edilebilir bir taşıyıcı, adjuvan veya aracı içerir.

公开(公告)号：MX348066B

公开(公告)日：2017-05-26

申请号：MX2015000091

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： HONGBO DENG ,  FRANCESCO G SALITURO ,  MICHAEL P CLARK ,  UPUL K BANDARAGE ,  RANDY S BETHIEL ,  IOANA DAVIES ,  JOHN P DUFFY ,  LUC J FARMER ,  HUAI GAO ,  WENXIN GU ,  JOSEPH M KENNEDY ,  BRIAN LEDFORD ,  MARK W LEDEBOER ,  EMANUELE PEROLA ,  TIANSHENG WANG ,  PAUL CHARIFSON ,  JOHN J COURT ,  DYLAN H JACOBS ,  FRANCOIS MALTAIS ,  M WOODS WANNAMAKER ,  RANDAL BYRN ,  YI ZHOU ,  CHAO LIN ,  MIN JIANG ,  STEVEN JONES ,  URSULA A GERMANN ,  ANN DAK-YEE KWONG

IPC: A61K31/506 ,  A61P31/16

Abstract: Métodos para inhibir la replicación de los virus de influenza en una muestra biológica o paciente o reducir la cantidad de virus de influenza en una muestra biológica o paciente y tratar influenza en un paciente que comprenden administrar a la muestra biológica o paciente una cantidad efectiva de un compuesto representado por la Fórmula Estructural (I) (ver Fórmula) (lA), o una sal farmacéuticamente aceptable del mismo, en donde los valores de Fórmula Estructural (lA) son como se describen en la presente. Un compuesto está representado por la Fórmula Estructural (IA) o una sal farmacéuticamente aceptable del mismo, en donde los valores de Fórmula Estructural (lA) son como se describen en la presente. Una composición farmacéutica comprende una cantidad efectiva del compuesto o sal farmacéuticamente aceptable del mismo y un portador, adyuvante o vehículo farmacéuticamente aceptable.

公开(公告)号：AU2010262905A1

公开(公告)日：2012-01-12

申请号：AU2010262905

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： PAUL CHARIFSON ,  CLARK MICHAEL P ,  BANDARAGE UPUL K ,  BETHIEL RANDY S ,  COURT JOHN J ,  HONGBO DENG ,  IOANA DRUTU ,  DUFFY JOHN P ,  LUC FARMER ,  HUAI GAO ,  WENXIN GU ,  JACOBS DYLAN H ,  KENNEDY JOSEPH M ,  LEDEBOER MARK W ,  BRIAN LEDFORD ,  FRANCOIS MALTAIS ,  EMANUELE PEROLA ,  TIANSHENG WANG ,  WOODS WANNAMAKER M ,  RANDAL BYRN ,  YI ZHOU ,  CHAO LIN ,  MIN JIANG ,  STEVEN JONES ,  GERMANN URSULA A

IPC: A61K31/506 ,  A61P31/16

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.